Christoph Schell

Current Position

Physician at the Institute of Surgical Pathology, Medical Center – University of Freiburg, Group Leader and Clinician-Scientist

Academic Education

2011 - 2014	PhD at SGBM graduate school, University of Freiburg
2002 - 2008	Medical School, LMU and TU Munich

Advanced Qualifications

2022	Board Certification, Pathology
2020	Habilitation in Experimental Pathology, University of Freiburg
2014	Dissertation (Dr. rer. nat.), Faculty of Biology, University of Freiburg
2012	Dissertation (Dr. med.), LMU University of Munich

Postgraduate Positions

2017 - present	Group Leader, Institute of Surgical Pathology, Medical Center - University of Freiburg
2016 - present	Pathology Resident, Institute of Surgical Pathology, Medical Center - University of Freiburg
2014 - 2015	Junior Group Leader, Department of Nephrology, Medical Center - University of Freiburg
2011 - 2015	Research Fellow, Department of Nephrology, Medical Center - University of Freiburg
2010 - 2011	Internal Medicine Residency, Medical Center - University of Freiburg
2009 - 2010	Internal Medicine Residency, University Medical Center Regensburg

Link to all publications of Christoph Schell: PubMed

Publications on CRC 1453 funding

Cosenza-Contreras M, Seredynska A, Vogele D, …, Huesgen PF, Kuehn EW, Kreutz C, Schell C, Schilling O. TermineR: Extracting information on endogenous proteolytic processing from shotgun proteomics data. Proteomics (2024). Arnold F, Kupferschmid L, Weissenborn P, …, Zareba P, Sagar, Rogg M, Schell C, Tanriver Y. Tissue-resident memory T cells break tolerance to renal autoantigens and orchestrate immune-mediated nephritis. Cell Mol Immunol (2024). Moeed A, Thilmany N, Beck F, …, Börries M, …, Zanetta P, Schell C, Schwemmle M, Weber A, Häcker G. The Caspase-Activated DNase drives inflammation and contributes to defense against viral infection. Cell Death Differ (2024). Guo H, Rogg M, Keller J, Scherzinger AK, Jäckel J, …, Groß O, Schell C,  Bechtel-Walz W. ADP-Ribosylation Factor-Interacting Protein 2 Acts as a Novel Regulator of Mitophagy and Autophagy in Podocytes in Diabetic Nephropathy. Antioxidants (2024). Riedhammer KM, Nguyen TMT, Kosukcu C, Calzada-Wack J, Li Y, …, Schlosser P, …, Wuttke M, …, Bergmann C, …, Antony D, …, Schell C, …, Köttgen A, Arnold S, Ozaltin F, Schmidts M, Hoefele J. Implication of transcription factor FOXD2 dysfunction in syndromic congenital anomalies of the kidney and urinary tract (CAKUT). Kidney Int (2023). Rogg M, Maier JI, Helmstädter M, Sammarco A, Kliewe F, …, Endlich N, Schilling O, Schell C. A YAP/TAZ-ARHGAP29-RhoA Signaling Axis Regulates Podocyte Protrusions and Integrin Adhesions. Cells (2023). Braun F, Abed A, Sellung D, Rogg M, Woidy M, …, Puelles VG, Schell C, Huber TB. Accumulation of α-synuclein mediates podocyte injury in Fabry nephropathy. J Clin Invest (2023). Vöing K, Michgehl U, Mertens ND. Picciotto C, Maywald ML, …, Schell C, …, George B, Weide T, Pavenstädt H. Disruption of the Rab7-Dependent Final Common Pathway of Endosomal and Autophagic Processing Results in a Severe Podocytopathy. J Am Soc Nephrol (2023). Seidel P, Rubarth A, Zodel K, Peighambari A, Neumann F, …, Adlesic M, …, Schell C, Börries M, …, Follo M, Albers J, Frew IJ. ATR represents a therapeutic vulnerability in clear cell renal cell carcinoma. JCI Insight (2022). Rückert T, Andrieux G, Börries M, Hanke-Müller K, Woessner NM, …, Schell C, …, Duyster J, Zeiser R, Köhler N. Human β-defensin 2 ameliorates acute GVHD by limiting ileal neutrophil infiltration and restraining T cell receptor signaling. Sci Transl Med (2022). Strohmeier V, Andrieux G, Unger S, Pascual-Reguant A, Klocperk A, …, Schell C, …, Börries M, Hasselblatt P, Warnatz K. Interferon-Driven Immune Dysregulation in Common Variable Immunodeficiency-Associated Villous Atrophy and Norovirus Infection. J Clin Immunol (2022). Marinescu IM, Rogg M, Spohn S, von Büren M, Kamps M, …, Grosu AL, Schell C, Zamboglou C. Ex vivo γH2AX assay for tumor radiosensitivity in primary prostate cancer patients and correlation with clinical parameters. Radiat Oncol (2022). Jiao H, Wachsmuth L, Wolf S, Lohmann J, Nagata M, …, Schell Ch, Young GR, Kassiotis G, Pasparakis M. ADAR1 averts fatal type I interferon induction by ZBP1. Nature (2022). Devane J, Ott E, Olinger EG, Epting D, Decker E, …, Börries M, Metzger P, Schell C, …, Schlevogt B, Sayer JA, Bergmann C. Progressive liver, kidney, and heart degeneration in children and adults affected by TULP3 mutations. Am J Hum Genet (2022). Rogg M, Maier JI, Ehle M, Sammarco A, Schilling O, Werner M, Schell C. NUP133 Controls Nuclear Pore Assembly, Transcriptome Composition, and Cytoskeleton Regulation in Podocytes. Cells (2022). Rogg M, Maier JI, Van Wymersch C, Helmstädter M, Sammarco A, …, Walz G, …, Benzing T, Huber TB, Schell C. α-Parvin Defines a Specific Integrin Adhesome to Maintain the Glomerular Filtration Barrier. J Am Soc Nephrol (2022). Maier JI, Rogg M, Helmstädter M, Sammarco A, Walz G, Werner M, Schell C. A Novel Model for Nephrotic Syndrome Reveals Associated Dysbiosis of the Gut Microbiome and Extramedullary Hematopoiesis. Cells (2021).